Beigene, Ltd. (NASDAQ:ONC – Get Free Report) COO Xiaobin Wu sold 21,267 shares of Beigene stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $240.07, for a total transaction of $5,105,568.69. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Xiaobin Wu also recently made the following trade(s):
- On Tuesday, February 18th, Xiaobin Wu sold 30,654 shares of Beigene stock. The stock was sold at an average price of $240.74, for a total transaction of $7,379,643.96.
Beigene Stock Up 4.6 %
Beigene stock opened at $255.37 on Friday. The firm has a market capitalization of $24.99 billion, a price-to-earnings ratio of -30.99, a price-to-earnings-growth ratio of 7.73 and a beta of 0.63. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. Beigene, Ltd. has a 12 month low of $126.97 and a 12 month high of $260.98.
Beigene Company Profile
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Further Reading
- Five stocks we like better than Beigene
- Financial Services Stocks Investing
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- Insider Selling Explained: Can it Inform Your Investing Choices?
- DuPont’s Electronics Spinoff: The Start of Something Big
- What is diluted earnings per share (Diluted EPS)?
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.
